GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-27 08:03:122018-02-27 08:03:12GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology. Read the full press release.
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-26 06:40:092018-02-26 10:49:41GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology
David S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy. Watch the video.
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-12 05:40:552018-02-12 05:40:55GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences
I think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-08 06:10:402018-02-21 08:29:27Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley
GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-05 08:30:352018-02-05 08:31:08Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-01-23 08:00:042018-01-24 06:05:57GigaGen Announces New Office Space in South San Francisco
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-01-16 08:00:042018-01-24 06:04:51GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2017-12-19 17:09:462017-12-19 13:02:45GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:30 p.m. PST on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2017-12-14 13:39:422017-12-19 13:02:45GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2017-08-29 13:14:132017-12-19 13:02:45GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires
GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols. Read the full story from Endpoints: An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2017-02-28 13:51:052017-12-19 13:02:45GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-11-01 12:39:562017-12-19 13:02:45GigaGen Announces $1.37M National Cancer Institute (NCI) Grant Award for Discovery and Development of New Oncology Therapies
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-10-13 22:16:572017-12-19 13:02:45GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-10-05 17:33:582017-12-19 13:02:45GigaGen to Present on Copying and Mining Immune Systems for Drug Discovery at the LakePharma Protein Engineering Symposium
GigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-09-27 13:53:182017-12-19 13:02:45GigaGen and Cellular Therapeutics Ltd Sign Collaboration for Novel TCR Discovery Directly from Patient’s T cells
GigaGen’s CEO, Dave Johnson, PhD, won the Best E-Poster Award for his presentation on “Manufacturing and Preclinical Validation of Recombinant Intravenous Immunoglobulin for Primary Immunodeficiency” in the Immunoglobulin and Immunomodulatory Therapy session on September 23, 2016 at the 17th biennial meeting of the European Society for Immunodeficiencies (“ESID”) in Barcelona, Spain. For details of the […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-09-23 19:28:192017-12-19 13:02:45GigaGen Wins Best E-Poster Award at ESID for Presentation of Preclinical Data for Recombinant Intravenous Immunoglobulin (IVIG)
GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-09-20 13:12:482018-01-24 06:55:48GigaGen Announces $1.5M NIH Grant Award for Development of Recombinant Intravenous Immunoglobulin
GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-09-13 13:58:592017-12-19 13:02:45GigaGen Announces Issue of US Patent for Polyclonal Antibody Production
GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology […]
GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology. Read the full press release.
Biotech Showcase 2018
News, UncategorizedDavid S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy. Watch the video.
GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, […]
Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley
News, UncategorizedI think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather […]
Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and […]
GigaGen Announces New Office Space in South San Francisco
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art […]
GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin […]
GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, […]
GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:30 p.m. PST on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]
GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming […]
GigaGen closes $50M deal with Grifols
News, UncategorizedGigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols. Read the full story from Endpoints: An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business
GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
News, UncategorizedGigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse […]
GigaGen Announces $1.37M National Cancer Institute (NCI) Grant Award for Discovery and Development of New Oncology Therapies
News, UncategorizedGigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development […]
GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio
News, UncategorizedListen to Moira Gunn’s interview with Dave Johnson, PhD, CEO of GigaGen on “Creating a Synthetic Immune System” on Biotech Nation Radio.
GigaGen to Present on Copying and Mining Immune Systems for Drug Discovery at the LakePharma Protein Engineering Symposium
News, UncategorizedGigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in […]
GigaGen and Cellular Therapeutics Ltd Sign Collaboration for Novel TCR Discovery Directly from Patient’s T cells
News, UncategorizedGigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the […]
GigaGen Wins Best E-Poster Award at ESID for Presentation of Preclinical Data for Recombinant Intravenous Immunoglobulin (IVIG)
News, UncategorizedGigaGen’s CEO, Dave Johnson, PhD, won the Best E-Poster Award for his presentation on “Manufacturing and Preclinical Validation of Recombinant Intravenous Immunoglobulin for Primary Immunodeficiency” in the Immunoglobulin and Immunomodulatory Therapy session on September 23, 2016 at the 17th biennial meeting of the European Society for Immunodeficiencies (“ESID”) in Barcelona, Spain. For details of the […]
GigaGen Announces $1.5M NIH Grant Award for Development of Recombinant Intravenous Immunoglobulin
News, UncategorizedGigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute […]
GigaGen Announces Issue of US Patent for Polyclonal Antibody Production
News, UncategorizedGigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]